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SUMMARY
WRN, the protein defective in Werner syndrome
(WS), is a multifunctional nuclease involved in DNA
damage repair, replication, and genome stability
maintenance. It was assumed that the nuclease
activities of WRN were critical for these functions.
Here, we report a nonenzymatic role for WRN in pre-
serving nascent DNA strands following replication
stress. We found that lack of WRN led to shortening
of nascent DNA strands after replication stress.
Furthermore, we discovered that the exonuclease
activity of MRE11 was responsible for the shortening
of newly replicated DNA in the absence of WRN.
Mechanistically, the N-terminal FHA domain of
NBS1 recruits WRN to replication-associated DNA
double-stranded breaks to stabilize Rad51 and to
limit the nuclease activity of its C-terminal binding
partner MRE11. Thus, this previously unrecognized
nonenzymatic function of WRN in the stabilization
of nascent DNA strands sheds light on the molecular
reason for the origin of genome instability in WS
individuals.
INTRODUCTION
During DNA replication, moving replication forks may encounter
obstacles like DNA lesions, DNA secondary structures, or pro-
tein-DNA complexes that can result in prolonged fork stalling
and collapse to generate DNA double-strand breaks (DSBs).
Alterations in the pathways involved in the recovery of stalled
or collapsed replication forks cause genome instability and
chromosomal rearrangements that are hallmarks of cancer cells
(Bartkova et al., 2005; Petermann and Helleday, 2010). One of
the multiple factors involved in DNA replication and repair is
WRN, a protein defective in Werner syndrome (WS). WS is a
rare autosomal recessive disorder characterized by premature
development of features that resemble aging. In addition, WS in-
dividuals have an increased cancer predisposition, leading pri-
marily to rare cancers that are mesenchymal in origin (Friedrich
et al., 2010; Goto, 1997). Primary cells derived from WS patients
exhibit elevated levels of chromosomal translocations, inver-
sions, and deletions of large segments of DNA and have a high
spontaneous mutation rate (Fukuchi et al., 1989; Salk et al.,
1981). Furthermore, WS cells are hypersensitive to several types
of DNA damaging agents including 4-nitroquinoline-1-oxide,
crosslinking agents (such asmitomycin C andcisplatin), campto-
thecin, and hydroxyurea (Pichierri et al., 2001; Poot et al., 1999,
2002). Moreover, WS cells display a prolonged S phase and
impaired replication fork progression (Poot et al., 1992; Sidorova
et al., 2008). Though these reports suggest that WRN plays
crucial roles in one or more genome stability maintenance path-
ways, the exact contribution of WRN in preventing genome
instability is unclear.
WRNbelongs to the RecQDNA helicase family.WRN is unique
among known RecQ helicases in having an N-terminal 30–50
exonuclease activity (Huang et al., 1998). WRN exonuclease
functions on a variety of structured DNA substrates, including
bubbles, stem loops, forks, and Holliday junctions, as well as
on RNA-DNA duplexes, implying roles for WRN in DNA replica-
tion, recombination, and repair (von Kobbe et al., 2003). The
30–50 DNA helicase activity (Gray et al., 1997) of WRN shows
substrate specificity similar to that for the exonuclease, suggest-
ing that the two enzymatic activities may have coordinated
functions. In addition to its nuclease activities, WRN also has
nuclease-independent functions during DNA replication and
repair (Chen et al., 2003; Kamath-Loeb et al., 2012), although
these nonenzymatic activities are not well understood.
WRN forms several dynamic subcomplexes with different
factors involved inmultiple biological processes.WRNphysically
interacts with Nijmegen breakage syndrome protein (NBS1) via
the forkhead-associated (FHA) domain of NBS1 in response to
DSBs, and this interaction is important for the posttranslational
modification of WRN (Kobayashi et al., 2010). WRN interacts
withMRE11 nuclease via NBS1 (Cheng et al., 2004); MRE11 pro-
motes WRN helicase activity, but WRN does not modulate the
nuclease activities of MRE11 (Cheng et al., 2004). WRN interacts
directly with Rad51; however, this interaction does not affect the
nuclease activities of WRN (Otterlei et al., 2006). Furthermore,
WRNdirectly and functionally associates with XPG, a DNA endo-
nuclease, and this interaction stimulates the helicase activity of
WRN (Trego et al., 2011). Furthermore, WRN not only interacts
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with NEIL1, but also stimulate its DNA glycosylase activities
(Popuri et al., 2010). Importantly, mutations in majority of these
genes lead to cancer-prone disorders. However, the contribu-
tions of WRN and its interacting partners to the maintenance of
genome stability are not well studied.
Though the nuclease and the nonnuclease activities of WRN
have been implicated in amultitude of DNAmetabolic pathways,
how WRN acts at the molecular level to prevent genome insta-
bility has not been determined. In this study, we report a nonen-
zymatic role for WRN in the stabilization of nascent DNA strands
at collapsed replication forks. We found that NBS1-mediated
recruitment of WRN to the replication-associated DSBs stabi-
lizes Rad51 and prevents the excessive degradation of nascent
DNA strands mediated by MRE11. Significantly, stabilization of
collapsed replication forks by the coordinated actions of WRN,
NBS1, Rad51, and MRE11 prevents chromosome instability. In
summary, our study reveals a previously uncharacterized nonca-
talytic role for WRN in the faithful duplication of the genome and
provides insights into the molecular reason for the development
of genome instability in WS individuals.
RESULTS
WRN Maintains Nascent DNA Strands in Response to
Replication Stress
Faithful and complete replication of genome in human cells is
essential for preventing the accumulation of cancer-promoting
mutations. WS, a disorder of premature aging manifested in
adolescence, is associated with an elevated risk of specific
types of cancers. Cells derived from WS patients display
elevated levels of chromosome instability. The WRN protein,
which is defective in WS, has been implicated in replication
fork progression and efficient restart of DNA replication (Ammaz-
zalorso et al., 2010; Sidorova et al., 2008, 2013). To better under-
stand the involvement of WRN in genome stability maintenance
in response to replication stress, we used a single-molecule DNA
fiber technique (Petermann et al., 2010; Schlacher et al., 2011)
(Figure S1A; Tables S1 and S2). In this assay, replicating DNA
before and during replication stress induced by camptothecin
(CPT) was sequentially labeled by incorporation of the thymidine
analogs 5-iodo-20-deoxyuridine (IdU) and 5-chloro-20-deoxyuri-
dine (CldU), respectively (Figure S1B). The assay was performed
in human telomerase reverse transcriptase (hTERT)-immortal-
ized WS cells (WS) and in WS cells complemented with wild-
type WRN (WS+WRN). In CPT-treated WS cells, 39% ± 5.7%
of all DNA fibers had both IdU and CldU tracts, whereas
73.2% ± 7.8% fibers contained both IdU and CldU in CPT-
treated WS+WRN cells (Figure S1C). These results indicated
that, as reported previously (Ammazzalorso et al., 2010), a
greater proportion of replication forks fail to restart in WS cells
in response to replication stress than in cells that express
WRN. Furthermore, we observed significantly lower number of
DNA fibers containing only CldU tracts, which represent origins
of replication, in WS cells in comparison to WS+WRN cells
(28.7% ± 0.09% and 62.6% ± 5.8% in WS and WS+WRN cells,
respectively, p < 0.014; Figure S1D). Importantly, we observed a
significantly higher percentage of DNA fibers that contained only
IdU tracts, which represent stalled forks, in CPT-treatedWS cells
relative to CPT-treated WS+WRN cells (61.02% ± 2.8% and
26.81% ± 3.9%,WS andWS+WRN, respectively, p < 0.034; Fig-
ure S1E). Our results suggest that a greater proportion of replica-
tion forks break in CPT-treated WS cells than in CPT-treated
WS+WRN cells.
Interestingly, we noticed that DNA fibers that contained only
IdU tracts were significantly shorter in CPT-treated WS cells
than in CPT-treated WS+WRN cells (3.5 ± 0.08 and 5.17 ±
0.35 mm, respectively, p < 0.022; Figure S1F), implying that the
collapsed replication forks are not maintained in WS cells.
We further verified these results by labeling WS and WS+WRN
cells with IdU for 30 min, after which replication stress was intro-
duced and the IdU-labeled DNA fibers were detected with
anti-bromodeoxyuridine (BrdU; mouse monoclonal) antibodies
(Figure S1G). Under these conditions, the IdU tract lengths
were the same in mock-treated WS and WS+WRN cells
(4.92± 0.01 and 5.08 ± 0.1 mm, respectively; Figure 1A). Similarly,
the IdU tract lengths were comparable between CPT- andmock-
treated WS+WRN cells (4.92 ± 0.01 and 4.86 ± 0.03 mm, res-
pectively). In contrast, the IdU tract lengths were significantly
shortened in CPT-treated WS cells relative to CPT-treated
WS+WRN cells (2.71 ± 0.05 and 4.86 ± 0.03 mm, respectively,
p < 0.0003; Figure 1A), reflecting a degradation of IdU tracts in
WS cells. Thus, in addition to roles in replication fork progression
and efficient restart, WRN also plays a role in the maintenance of
nascent DNA strands in response to CPT-induced replication
stress.
Next, we verified whether the shortening of nascent DNA
tracts is unique to cells derived from WS patients or whether
shortening also happens in other cell types. We depleted WRN
from HeLa cells usingWRN-specific small hairpin RNA (shRNA)
and examined the nascent DNA tract lengths. As in WS cells,
nascent DNA tract lengths were significantly shortened in CPT-
treated, WRN-depleted HeLa cells compared to CPT-treated
HeLa cells transfected with a control shRNA (3.57 ± 0.13 and
5.15 ± 0.11 mm, respectively, p < 0.0001; Figure 1B). This result
confirmed that WRN is required for the maintenance of nascent
DNA strands in non-WS cells.
To further clarify whether the role of WRN in replication fork
maintenance is limited to human cells, we performed experi-
ments in mouse embryonic fibroblasts (MEFs) derived from
WRN-knockout mice (Lombard et al., 2000). As shown in Fig-
ure 1C, the nascent DNA tract lengths in CPT-treated WRN/
MEFs were significantly shorter than in the CPT-treated wild-
type MEFs (3.28 ± 0.22 and 5.02 ± 0.12 mm, respectively, p <
0.0003). Thus, WRN is involved in the maintenance of nascent
DNA strands in response to CPT-induced replication stress in
different mammalian cell types.
Evidence indicates that CPT induces both replication stalling
and DNA breaks in a concentration-dependent manner. Low
doses (25–100 nM) of CPT induce replication fork slowing and
reversal without inducing detectable levels of DSBs, and at
higher concentrations (>100 nM) CPT induces DNA breaks (Berti
et al., 2013; Ray Chaudhuri et al., 2012). To discriminate whether
WRN is required for the stability of nascent DNA strands in
response to replication fork stalling or replication-associated
DSBs, we measured IdU tract lengths in cells treated with low
doses of CPT. As shown in Figure 1D, IdU tract lengths in WS
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Figure 1. WRN Stabilizes Nascent DNA Strands in Response to Replication Stress
(A) IdU-tract-length distribution in hTERT-immortalized WS and WS cells complemented with wild-type WRN (WS+WRN), treated with or without 1 mM CPT for
5 hr. See also Figure S1 and Tables S1 and S2.
(B) Nascent DNA-tract-length distribution in HeLa cells transfected with eitherWRN or control shRNA, treated with or without 1 mM CPT for 5 hr. Inset, western
blot for WRN expression in HeLa cells transfected with WRN shRNA and control shRNA.
(C) IdU-tract-length distribution in WRN-deficient mouse embryonic fibroblasts (MEFs), treated with or without 1 mM CPT for 5 hr.
(D) Nascent DNA-tract-length distribution in hTERT-immortalized WS and WS cells complemented with wild-type WRN (WS+WRN), treated with 25 or 100 nM
CPT for 5 hr.
(E) IdU-tract-length distribution in WS and WS+WRN cells treated with 4 mM HU for 5 hr.
(F) Nascent DNA-tract-length distribution in BRCA2-deficient V-C8 and V-C8+BRCA2 cells, treated with 4 mM HU for 5 hr.Cell Reports 9, 1387–1401, November 20, 2014 ª2014 The Authors 1389
cells treated with 25 and 100 nM CPT (5.04 ± 0.01 and 5.00 ±
0.05 mm, respectively) were similar to lengths in WS+WRN cells
treated with 25 and 100 nMCPT (5.07 ± 0.02 and 5.04 ± 0.04 mm,
respectively). These results suggest that WRN is not involved in
the maintenance of nascent DNA tracts in response to replica-
tion fork stalling.
Treatment of cells for a short time with hydroxyurea (HU)
causes replication fork stalling, but it does not lead to DSBs for-
mation (Petermann et al., 2010). To further rule out the possibility
that WRN is not involved in the maintenance of nascent DNA
strands in response to replication fork stalling, we exposed WS
and WS+WRN cells to 4 mM HU for 5 hr and then quantified
the nascent DNA tract lengths. Similar to low-dose CPT treat-
ment, the nascent DNA tract lengths in HU-treated WS cells
were comparable to those in HU-treated WS+WRN cells (4.58
± 0.03 and 4.89 ± 0.05 mm, respectively; Figure 1E). However, us-
ing similar HU treatment conditions, nascent DNA strands were
significantly shortened in HU-treated BRCA2-defective V-C8
cells relative to V-C8 cells complemented with BRCA2 (3.26 ±
0.06 and 5.16 ± 0.01 mm, respectively, p < 0.02; Figure 1F), con-
firming a previous finding (Schlacher et al., 2011). Taken
together, these results clearly reveal that, unlike BRCA2, WRN
is not important for the stabilization of nascent DNA strands in
response to replication fork stalling.
To further evaluate whether WRN is particularly important for
the maintenance of nascent DNA strand in response to replica-
tion breaks or important only for replication breaks induced by
CPT, we examined IdU tract lengths after treatment of cells
with HU for 24 hr; under these conditions, the stalled replication
forks are broken (Petermann et al., 2010). As shown in Figure 2A,
IdU track lengths in HU-treated WS+WRN cells were compara-
ble to those in mock-treated WS+WRN cells (5.00 ± 0.04 and
5.09 ± 0.03 mm, respectively). In contrast, IdU track lengths
were significantly shortened in HU-treated WS cells relative to
HU-treated WS+WRN cells (3.53 ± 0.15 and 5.0 ± 0.04 mm,
respectively, p < 0.03; Figure 2A). These results suggest that
WRN is critical for the maintenance of nascent DNA strands in
response to replication-associated DSBs and is not specific
only to CPT-induced replication breaks.
To further confirm the contribution of WRN to nascent DNA
strand maintenance in response to replication breaks, we in-
hibited the formation of CPT-induced replication-mediated
DSBs in cells using the DNA polymerase inhibitor aphidicolin
(APH; Figure 2B, top) (Pommier et al., 2010; Takemura et al.,
2006). Treatment of WS cells with APH entirely prevented
the CPT-dependent shortening of nascent DNA strands in WS
cells (Figure 2B, bottom). The nascent DNA tract lengths
in APH+CPT-treated WS cells were comparable to those in
APH+CPT-treated WS+WRN cells (4.93 ± 0.3 and 5.14 ±
0.05 mm, respectively; Figure 2B, bottom). Collectively, these re-
sults reveal that WRN is required for the stabilization of nascent
DNA strands in response to replication breaks.
WRN Is Recruited to the Sites of Replication-Associated
DSBs and It Colocalizes with RPA2, Rad51, NBS1, and
MRE11
Because WRN maintains newly synthesized DNA strands after
replication stress, we next verified that WRN is recruited to the
sites replication in response to CPT-induced replication stress.
As shown in Figure S2A,WRNclearly juxtaposedwith the 5-ethy-
nyl-20-deoxyuridine-labeled replication sites in CPT-treated
early-, mid-, and late-S phase cells, indicating that WRN is
indeed recruited to the sites of replication in all S phase cells in
response to replication stress. Further, as reported previously
(Cheng et al., 2005; Kobayashi et al., 2010), we noticed that
most WRN foci (82% ± 8%) clearly overlapped with gH2AX
foci in CPT-treated but not in mock-treated cells (Figure S2B),
confirming that WRN is recruited to the sites of replication-asso-
ciated DSBs. As with previous reports (Futami et al., 2007; Patro
et al., 2011; Sakamoto et al., 2001), we observed colocalization
of 70% ± 6% of WRN foci with RPA2 and Rad51 foci in CPT-
treated cells (Figures S2C and S2D). In addition, as reported pre-
viously (Cheng et al., 2004), we also observed colocalization of
WRN and NBS1 foci (71% ± 9%) in CPT-treated cells (Fig-
ure S2E). Furthermore, 53% ± 6% of WRN foci overlapped
with MRE11 foci in CPT-treated cells (Figure S2F), confirming a
previous report (Pichierri and Franchitto, 2004). Taken together,
these data demonstrate that WRN colocalizes with many of its
known interacting partners at replication-associated DSBs.
Nuclease Activities of WRN Are Not Required for the
Stabilization of Nascent DNA Strands in Response to
Replication-Associated DSBs
WRN contains multiple protein-protein interaction domains and
has DNA binding motifs in the C-terminal domain (Lan et al.,
2005; von Kobbe et al., 2003). It also has exonuclease (Huang
et al., 1998) and helicase activities (Gray et al., 1997). We set
out to identify the domain and the enzymatic activity that are
involved in the maintenance of nascent DNA strands in response
to replication breaks. We stably expressed Flag+EGFP tagged
1–366 (WRN1–366), 250–366 (WRN250–366), and 940–1,432
(WRN940–1432) amino acid regions of WRN and the exonuclease
defective (WRNE84A) and the helicase defective (WRNK577A)
full-length WRN constructs in WS cells (Figures 3A, S3A, and
S3B). Subsequently, we used these cell lines to identify the
WRN domain that is recruited to replication-associated DSBs.
As shown in Figure 3B, WRN1–366, but not the WRN250–366 and
WRN940–1432 domains, formed distinct foci in response to CPT-
induced replication stress. Further, indirect immunostaining
with 2 mm anti-WRN revealed that both exonuclease (WRNE84A)
and helicase (WRNK577A) defective WRNs formed distinct foci
in response to CPT (Figure 3B). In response to CPT treatment,
55% ± 7.7% of WRN1–366, 71% ± 5.4% of WRNE84A, and
82% ± 6.1% of WRNK577A foci overlapped with gH2AX foci.
Thus, WRN1–366, exonuclease-defective and helicase-defective
WRN, but not WRN250–366 and WRN940–1432, were recruited to
the sites of replication-associated DSBs.
To verify that the recruitment of WRN1–366 to the sites of repli-
cation breaks functioned in the maintenance of nascent DNA
strands, we evaluated lengths of IdU-labeled fragments in WS
cells stably expressing WRN1–366. The IdU tract lengths in
CPT-treated WS+WRN1–366 cells were comparable to those in
mock-treated WS+WRN1–366 cells (4.82 ± 0.02 and 5.02 ±
0.08 mm, respectively; Figure 3C). Therefore, the WRN1–366 frag-
ment is required for the maintenance of nascent DNA strands in
response to replication stress.
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Figure 2. WRN Preserves Nascent DNA
Strands in Response to Replication Breaks
(A) IdU-tract-length distribution in WS and
WS+WRN cells treated with 4 mM HU for 24 hr.
(B) Nascent DNA-tract-length distribution in WS and
WS+WRN cells, exposed to 2 mM aphidicolin/1 mM
CPT or CPT only for 5 hr.
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Figure 3. N-Terminal Region of WRN1–366 Is
Sufficient to Stabilize Nascent DNA Strands
in Response to Replication-Associated
DSBs
(A) Schematics show different functional regions
of human and mouse WRN, and the various WRN
domains used in the study. TDD, WRN-WRN
interaction domain; HRDC, helicase and RNase D
C-terminal domain; RQC, RecQ conserved
domain; NLS, nucleolar localization signal; E84A,
exonuclease mutant; K577A, helicase mutant.
See also Figure S3.
(B) WS cells stably expressing 1–366 aa, 250–366
aa, 940–1,432 aa, exonuclease-defective (E84A),
and helicase-defective (K577A) WRN were
treated with 1 mM CPT for 1 hr. After 5 hr, cells
were immunostained with anti-gH2AX and anti-
WRN. Representative confocal microscope im-
ages are shown. Scale bars, 5 and 10 mm.
(C–E) IdU-tract-length distribution in WS cells
stably expressing WRN1–366 (C), WRN250–366 (D),
and the C-terminal region containing HRDC and
DNA binding motifs (940–1,432 aa) (E), treated
with or without 1 mM CPT for 5 hr.
(F) Nascent DNA-tract-length distribution in
mouse embryonic fibroblasts (MEFs) derived from
wild-type (WT) and helicase domain deficient
WRN (WRNDhel/Dhel) mice, treated with or without
1 mM CPT for 5 hr. Inset, ethidium-bromide-
stained agarose gel picture for WT and WRNDhel/
Dhel mice genotyping.
(G and H) IdU-tract-length distribution in WS cells
stably expressing exonuclease-defective (E84A;
G) and helicase-defective (K577A; H) WRN,
treated with or without 1 mM CPT for 5 hr. Inset,
western blot analyses for WT, E84A, and K577A
WRN expression in WS cells.
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Because the WRN1–366 fragment contains both exonuclease
(1–250 aa) and WRN-WRN interaction (250–366 aa) domains
(Perry et al., 2006, 2010), we set out to further narrow down
the region of WRN required for the maintenance of nascent
DNA strands. The IdU tract lengths were significantly shortened
in CPT-treated WS cells stably expressing WRN250–366 relative
to mock-treated WS+WRN250–366 cells (3.7 ± 0.32 and 5.3 ±
0.01 mm, respectively, p < 0.002; Figure 3D). Thus, the WRN-
WRN interaction domain is not involved in the maintenance of
nascent DNA strands.
We then examined the involvement of the C-terminal domain
(940–1,432 aa), which contains the DNA binding motifs (Lan
et al., 2005; von Kobbe et al., 2003), and the HRDC domain in
nascent DNA strand maintenance. We observed that the IdU
tract lengths were significantly reduced in CPT-treated
WS+WRN940–1432 cells as compared with the mock-treated
WS+WRN940–1432 cells (3.47 ± 0.32 and 4.86 ± 0.1 mm, respec-
tively, p < 0.002; Figure 3E). Thus, the C-terminal domain (940–
1,432 aa) containing the DNA binding motifs and the HRDC
domain of WRN is not required for the maintenance of nascent
DNA strands.
To rule out the possibility that the lack of nascent DNA
strand maintenance in CPT-treated WS+WRN250–366 and
WS+WRN940–1432 cells could be due to improper folding, we
examined the interaction of WRN250–366 with full-length WRN
and WRN940–1432 with the Ku70/80 heterodimer. As previously
demonstrated (Perry et al., 2010), the WRN250–366 domain inter-
acted with full-length WRN in vivo (Figure S3C). Similarly, the
WRN940–1432 domain clearly interacted with Ku70/80 hetero-
dimer in vivo (Figure S3D), confirming a previous study (Cooper
et al., 2000). These results clearly suggest that the lack of
complementation of nascent DNA strand maintenance by
WRN250–366 andWRN940–1432 domains is not due to the improper
folding of these constructs.
To determine the contribution of helicase domain, we used
MEFs derived from WRN helicase domain-deficient mouse
(WRNDhel/Dhel) (Lebel and Leder, 1998). As shown in Figure 3F,
the IdU tract lengths were similar in CPT-treated and mock-
treated WRNDhel/Dhel MEFs (5.11 ± 0.18 and 5.19 ± 0.14 mm,
respectively), suggesting that the central helicase domain of
WRN does not contribute to the stabilization of nascent DNA
strands in response to replication stress. Next, we examined
the involvement of exonuclease and helicase activities in the
stabilization of replication forks. The nascent DNA strand lengths
in CPT-treated WS cells expressing WRNE84A were similar to
those in mock-treated WS+WRNE84A cells (5.12 ± 0.12 and
5.14 ± 0.14 mm, respectively; Figure 3G). Similarly, the IdU tract
lengths in CPT-treated WS cells expressing WRNK577A were
comparable to those in mock-treated WS+WRNK577A cells
(4.98 ± 0.07 and 5.11 ± 0.01 mm, respectively; Figure 3H).
Thus, the nuclease activities of WRN are not important for the
stabilization of newly replicated genome.
Subsequently, we verified whether the physical presence of
WRN at replication breaks is critical for the maintenance of
nascent DNA strands. For this purpose, we disrupted the recruit-
ment of WRN to replication breaks in HeLa cells by stably ex-
pressing the WRN-WRN interaction domain (Perry et al., 2010).
As shown in Figure S4A, recruitment of endogenous WRN to
the sites of replication breaks was attenuated in CPT-treated
HeLa cells stably expressing WRN250–366. Further, we noticed
that the nascent DNA strands were significantly shortened in
CPT-treated HeLa+WRN250–366 cells relative to mock-treated
HeLa+WRN250–366 cells (3.46 ± 0.1 and 5.21 ± 0.07 mm, respec-
tively, p < 0.0001; Figure S4B). Therefore, it is not the nuclease
activities of WRN, but the physical presence of WRN at the sites
of replication breaks is critical for the maintenance of nascent
DNA strands.
NBS1 Recruits WRN to Stabilize Collapsed Replication
Forks
Though the WRN1–366 fragment lacks any known DNA binding
motif, it is sufficient to maintain nascent DNA strands. Therefore,
it is possible that this function of WRN is mediated indirectly via
one of its binding partners. The FHA domain of NBS1 is known to
recruit WRN to the sites of DSBs (Cheng et al., 2004; Kobayashi
et al., 2010), and theWRN-NBS1 interaction is mediated through
the N-terminal region of WRN (Cheng et al., 2004) (Figure 4A). As
shown in Figure 4B, WRN is recruited to replication-associated
DSBs in CPT-treated NBS+WT NBS1 cells but not in NBS or
NBS+DFHA-NBS1 cells. Further, DNA-fiber-length measure-
ments revealed no substantial differences in the IdU tract lengths
between CPT- and mock-treated NBS cells expressing full-
length NBS1 (NBS+WT; 5.19 ± 0.09 and 5.27 ± 0.23 mm, respec-
tively; Figure 4C). In contrast, nascent DNA strand lengths were
significantly shortened in CPT-treated NBS cells expressing
DFHA-NBS1 relative to mock-treated NBS+DFHA-NBS1 cells
(3.32 ± 0.07 and 5.15 ± 0.02 mm, respectively, p < 0.00001;
Figure 4D). Thus, the FHA domain of NBS1 recruits WRN to repli-
cation-associated DSBs, and this interaction is critical for the
stabilization of newly replicated DNA.
MRE11 Degrades Nascent DNA Strands in the Absence
of WRN
When we examined the nascent DNA strand lengths in CPT-
treated NBS cells, the IdU tract lengths were similar to those in
mock-treated NBS cells (5.04 ± 0.1 and 5.24 ± 0.07 mm, respec-
tively; Figure 5A), implying that the newly replicated DNA ismain-
tained in the absence of NBS1. Evidence suggests that the
recruitment of MRE11 to the nucleus and damaged DNA sites
is NBS1 dependent (Sakamoto et al., 2007). In the absence of
full-length NBS1, MRE11 cannot be recruited to the replica-
tion-associated DSBs; hence, the nascent DNA strands are
intact in NBS cells. In the NBS+DFHA-NBS1 cells, MRE11 is
recruited to replication-associated DSBs, but WRN is not; there-
fore, the nascent DNA tracts are shortened in NBS+DFHA-NBS1
cells. Further, a number of studies have found that MRE11 de-
grades nascent DNA strands in the absence of BRCA2, Fanconi
anemia (FA) factors, and Rad51 in response to replication stalling
(Hashimoto et al., 2010; Schlacher et al., 2011, 2012). For these
reasons, we hypothesize that MRE11 is the nuclease that de-
grades nascent DNA strands in the absence of WRN. To verify
this hypothesis, we first determined the rate of nascent DNA
strand degradation in WS cells. As shown in Figure 5B, exposure
of WS cells to CPT for different times resulted in a gradual short-
ening of nascent DNA strands (5.1 ± 0.16, 4.53 ± 0.4, 3.7 ± 0.12,
and 2.71 ± 0.05 mm, in mock-treated cells and in CPT-treated
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cells at 1, 2.5, and 5 hr, respectively). The calculated rate of
nascent DNA strand degradation was 0.54 ± 0.05 mm/hr. The
slow kinetics of nascent DNA strand degradation and lack of
replication fork degradation in NBS cells together reveal that
the nuclease activities of MRE11 are responsible for the degra-
dation of nascent DNA strands in the absence of WRN.
Subsequently, we examined the direction of nascent DNA
strand degradation in WS cells by sequentially labeling the repli-
cating DNA first with CldU and then with IdU. The IdU:CldU ratio
was significantly smaller in CPT-treated WRN-depleted HeLa
cells than in mock-treated WRN-depleted HeLa cells (0.62 ±
0.09 and 1 ± 0.01, respectively, p < 0.0097; Figure 5C). Impor-
tantly, we observed the shortening of very recently replicated
DNA (i.e., IdU-labeled DNA) in CPT-treated WRN-depleted
HeLa cells. MRE11 has 30–50 exonuclease and endonuclease ac-
tivities (Shibata et al., 2014), and the nascent DNA strands were
degraded from 30–50 direction, supporting our hypothesis that
the degradation of nascent DNA strands in WRN-defective cells
is mediated by the exonuclease activity of MRE11.
When the exonuclease activity of MRE11 was inhibited with
mirin (Dupre´ et al., 2008), the IdU tract lengths were not short-
ened in CPT-treated cells, and the DNA fiber lengths in
CPT+mirin-treated WS cells were comparable to that of mock+
mirin-treated WS cells (4.87 ± 0.01 and 5.37 ± 0.42 mm, respec-
tively; Figure 5D). To rule out the possibility of nonspecific inhib-
itory activities of mirin, we depleted MRE11 in WS cells using
MRE11 shRNA and then measured the nascent DNA tract
lengths. As shown in Figure 5E, the DNA fiber lengths were
similar in CPT-treated MRE11-depleted WS cells and in mock-
treated WS+MRE11-shRNA cells (5.14 ± 0.03 and 5.17 ±
0.01 mm, respectively). To further validate these findings, we
depleted WRN in MRE11-defective (ataxia telangiectasia-like
Figure 4. Nascent DNA Strand Maintenance Function of WRN Is NBS1 Dependent
(A) Diagram shows different functional protein-protein interaction domains of NBS1. FHA, Forkhead-associated domain; BRCT, BRCA1 C terminus domain;
WRN, ATM, and MRE11, WRN, ATM, and MRE11 interaction domains, respectively.
(B) Representative confocal images show recruitment of WRN to the sites of replication-associated DSBs in NBS, NBS+WT NBS1, and NBS+DFHA-NBS1 cells
treated with or without 1 mM CPT for 5 hr. Cells were immunostained with anti-WRN and anti-gH2AX. Scale bars, 5 mm.
(C and D) Nascent DNA-tract-length distribution in NBS cells stably expressing full-length (C) andDFHA (D) NBS1, treated with or without 1 mMCPT for 5 hr. Inset,
western blot analysis for full-length and DFHA NBS1 expression in NBS cells.
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Figure 5. MRE11 Degrades Nascent DNA Strands in Response to Collapsed Replication Forks in the Absence of WRN
(A) IdU-tract-length distribution in NBS1-deficient cells, treated with or without 1 mM CPT for 5 hr. Inset, western blot analysis for NBS1 expression in NBS and
NBS+NBS1 cells.
(B) Nascent DNA-tract-length distribution in WS cells, treated with or without 1 mM CPT for 1, 2.5, and 5 hr.
(C) Distribution curves of the ratio of IdU/CldU tract lengths in HeLa cells transfected with eitherWRN or control shRNA treated with or without 1 mMCPT for 5 hr.
(D) IdU-tract-length distribution in WS cells exposed to 100 mM mirin/1 mM CPT or DMSO/1 mM CPT for 5 hr.
(E) Nascent DNA-tract-length distribution in WS cells transfected with eitherMRE11 or control shRNA, treated with or without 1 mM CPT for 5 hr. Inset, western
blot for MRE11 expression in WS cells transfected with MRE11 shRNA and control shRNA.
(F) IdU-tract-length distribution in MRE11-defective ATLD cells transfected with either control orWRN shRNA, treated with or without 1 mM CPT for 5 hr. Inset,
western blots for WRN and MRE11 expression in ATLD cells.
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disorder [ATLD]) cells and found that the nascent DNA tract
lengths were comparable in CPT-treated and in mock-treated
WRN-depleted ATLD cells (5.11 ± 0.01 and 5.14 ± 0.01 mm,
respectively; Figure 5F). Collectively, these data indicate that
MRE11 is themain nuclease that degrades nascent DNA strands
after replication breaks in the absence of WRN.
WRN and Rad51 Function Additively to Block
MRE11-Mediated Degradation of Nascent DNA Strands
How does WRN limit the exonuclease activity of MRE11 on the
nascent DNA strands at replication-associated DSBs? WRN
maymodulate either the nuclease activity ofMRE11 or the stabil-
ity of the interaction of Rad51 with replication breaks. Because
WRN neither stimulates nor inhibits the nuclease activities of
MRE11 (Cheng et al., 2004), we excluded the possibility of
WRN-mediated regulation of the nuclease activity of MRE11.
Because WRN directly interacts with Rad51 (Otterlei et al.,
2006) and colocalizes with Rad51 at the replication-associated
DSBs (Figure S2D), it is possible that WRN and Rad51 function
together in the stabilization of the broken replication forks. To
determine whether WRN and Rad51 function cooperatively to
protect nascent DNA strands, we first evaluated the involvement
of Rad51 in the maintenance of nascent DNA strands using
HT1080 cells that stably express tetracycline-inducible Rad51
shRNA. The DNA fiber lengths were significantly shortened in
CPT-treated Rad51-depleted HT1080 cells relative to CPT-
treated control HT1080 cells (3.36 ± 0.11 and 5.09 ± 0.01 mm,
respectively, p < 0.002; Figure 6A), confirming a previous report
(Hashimoto et al., 2010). Further, we validated these results us-
ing a small-molecule B02 that prevents the formation of Rad51
nucleofilaments (Huang et al., 2012). As shown in Figure S5A,
pretreatment of WS and WS+WRN cells with B02 prevented
the formation of Rad51 foci in 77% ± 11% of the cells. In cells
pretreated with B02, nascent DNA strands were shorter in
CPT-treated than in mock-treated WS+WRN cells (3.4 ± 0.26
and 5.1 ± 0.02 mm, respectively, p < 0.01; Figure 6B). Moreover,
similar to a previous finding (Hashimoto et al., 2010), treatment of
WS+WRN cells with mirin, B02, and CPT completely prevented
the degradation of IdU tracts. The nascent DNA tract lengths
were comparable to those of mock+B02-treated WS+WRN cells
(4.7 ± 0.2 and 4.8 ± 0.05 mm, respectively; Figure 6B), implying
that MRE11 degrades nascent DNA tracts in the absence of
Rad51. Like WRN, Rad51 blocks the MRE11-meditated degra-
dation of nascent DNA strands in response to CPT-induced repli-
cation stress.
Recent reports indicate that BRCA2/FA factors and Rad51
act epistatically to protect the nascent DNA strands (Schlacher
et al., 2011, 2012). Further, we noticed that the extent of nascent
DNA strand degradation was comparable between WRN- and
Rad51-deficient cells. To determine the relative contribution of
WRN and Rad51 to the stability of replication forks, we downre-
gulated the expression of WRN and Rad51 in the same cell (Fig-
ure 6C, inset). Surprisingly, we found that the nascent DNA
tracts in CPT-treated WRN shRNA/Rad51 shRNA cells (2.6 ±
0.3 and 5.03 ± 0.1 mm, CPT and mock, respectively, p <
0.0002) were shorter than in CPT-treated cells that expressed
only one of the shRNAs (Figure 6C). Additionally, we observed
similar results when WS cells were first treated with B02 and
then exposed to CPT (2.73 ± 0.21 and 4.78 ± 0.06 mm, CPT
and mock treatment, respectively, p < 0.0001; Figure 6D).
Further, addition of mirin prevented the degradation of nascent
DNA strands in CPT-treated HT1080 cells that expressed both
WRN and Rad51 shRNAs (5.03 ± 0.1 and 4.9 ± 0.15 mm,
mock and CPT treatment, respectively; Figure 6C) and in CPT-
treated WS+B02 cells (4.78 ± 0.06 and 4.58 ± 0.19 mm, mock
and mirin, respectively; Figure 6D). Collectively, these results
demonstrate that, unlike BRCA2/FA factors and Rad51, WRN
and Rad51 function additively to protect nascent DNA strands
after replication stress.
Additive effects of WRN and Rad51 in the protection of
replication forks suggest that these proteins are functioning in
independent pathways. If this is the case, then how does WRN
protect nascent DNA strands in response to replication breaks?
Evidence suggests thatWRNdirectly interacts with Rad51 (Otter-
lei et al., 2006). Further, it has recently been shown that stabi-
lization of Rad51 at stalled replication forks in BRCA2 and
FA-pathway-defective cells blocks MRE11-mediated degrada-
tion (Schlacher et al., 2011, 2012). Furthermore, the level of
Rad51expression inWScellswassimilar to thatofWS+WRNcells
(Figure S5B). Therefore, it is possible that WRN might stabilize
Rad51 at collapsed replications forks to block the MRE11-medi-
ated degradation of nascent DNA strands. To determine whether
WRN is involved in the stabilization of Rad51 in response to repli-
cation stress, firstwe enumerated thenumber ofRad51 foci inWS
and WS+WRN cells. We noticed that the number of Rad51 foci
remain unchanged in WS+WRN cells exposed to CPT for 1, 2.5,
and 5 hr (86.1 ± 11.4, 79.8 ± 7.1, and 83.8 ± 12.4 foci per cell,
respectively; Figures S5C and S5D). On the contrary, similar to a
previous report (Pichierri et al., 2001), the number of Rad51 foci
was reduced significantly inWS cells (24.1 ± 9.3 foci per cell) rela-
tive to WS+WRN cells exposed to CPT for 5 hr (Figures S5C and
S5D). Subsequently,we verified these results by a chromatin frac-
tionation assay. As shown in Figure S5E, the level of chromatin-
bound Rad51 was lower in CPT-treated WS cells relative to
CPT-treated WS+WRN cells. Overall, these results suggest that
WRN is somehow involved in the stabilization of Rad51 at replica-
tion-associated DSBs.
To test whether stabilization of Rad51 at replication breaks
prevents MRE11-mediated degradation of nascent DNA
strands, we expressed a Rad51 mutant (K133R) in WS cells (Fig-
ure S5F). ATP hydrolysis by Rad51 is required for efficient disso-
ciation of Rad51 from the DNA (van Mameren et al., 2009). The
Rad51 K133R mutant lacks ATPase activity, and it forms stable
DNA-Rad51 complexes and promotes strand exchange in vitro
(Morrison et al., 1999). In WS cells overexpressing the Rad51
K133R mutant, the nascent DNA tract lengths were not short-
ened in CPT-treated cells compared to mock-treated cells
(4.38 ± 0.04 and 4.46 ± 0.01 mm, respectively; Figure 6E).
Furthermore, Rad51 levels are often elevated in tumor cells
(Brown and Holt, 2009), and the formation of stable Rad51 fila-
ments are observed in these cells (Raderschall et al., 2002).
We tested whether overexpression of Rad51 in WS cells
stabilizes Rad51 filaments and therefore protects replication
forks (Figure S5F). As shown in Figure 6F, overexpression of
wild-type Rad51 partially protected the nascent DNA tracts in
CPT-treated WS cells (3.99 ± 0.12 and 4.52 ± 0.02 mm, CPT
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Figure 6. WRN and Rad51 Additively Protect Nascent DNA Strands from MRE11-Mediated Degradation
(A) IdU-tract-length distribution in HT1080 cells stably expressing tetracycline-inducibleRad51 shRNA, treatedwith or without 1 mMCPT for 5 hr. Inset, analysis of
Rad51 expression in HT1080 cells with or without doxycycline treatment for 72 hr.
(B) Nascent DNA-tract-length distribution in WS+WRN cells exposed to 100 mM B02/1 mM CPT or 1 mM CPT only for 5 hr. See also Figure S5.
(C) IdU-tract-length distribution in HT1080 cells stably expressing tetracycline-inducible Rad51 shRNA transfected withWRN shRNA, exposed to 100 mMmirin/
1 mM CPT or 1 mM CPT only for 5 hr. Inset, western blots for Rad51 and WRN expression in HT1080 cells.
(D) Nascent DNA-tract-length distribution in WS cells exposed to 100 mM B02/1 mM CPT or 100 mM B02/100 mMmirin/1 mM CPT or 1 mM CPT only for 5 hr. See
also Figure S5.
(E and F) IdU-tract-length distribution in WS cells transfected with K133R mutant (E) and wild-type (F) Rad51, treated with or without 1 mM CPT for 5 hr. Inset
shows overexpression of wild-type and K133R mutant Rad51 in WS cells. See also Figure S5.
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andmock, respectively). Thus, the stabilization Rad51 at replica-
tion breaks in WRN-defective cells blocks MRE11-mediated
degradation of nascent DNA strands.
WRN Is Critical for ChromosomeStability in Response to
CPT Treatment
To investigate the contribution of WRN to maintenance of
genome stability in response to replication stress, we evaluated
gross chromosomal aberrations in metaphase cells derived from
WS andWS+WRN cells exposed to CPT for 5 hr. Classical chro-
mosome analysis of metaphase spreads revealed that exposure
of WS cells to CPT significantly elevated the number of chromo-
somal aberrations per mitotic cell relative to the number per
mitotic WS+WRN cell (p = 0.0006; Figure S6A). The average
number of aberrations per WS cell treated with CPT was 2.29
± 0.02, but it was only 0.56 ± 0.03 per WS+WRN cell exposed
to CPT. Further, the percentage of metaphases with gaps,
breaks, and radials was significantly higher in WS cells relative
to WS+WRN cells (Figure S6B). Number of gaps, breaks, trira-
dial, chromosomal breaks, and end-end fusions were also
significantly elevated in CPT-treated WS cells compared to
CPT-treated WS+WRN cells (Figure S6C). Thus, WRN plays an
important role in the suppression of chromosome instability in
response to replication stress.
WRN, NBS1, Rad51, andMRE11 Assemble onto Nascent
DNA Strands
To verify whether WRN, NBS1, Rad51, and MRE11 assemble
onto nascent DNA strands, we carried out chromatin immuno-
precipitation (ChIP) assay (Petermann et al., 2010). As shown
in Figure 7A, WRN, NBS1, Rad51, and MRE11 clearly interacted
with the nascent DNA strands in WS+WRN cells. Interestingly,
we noticed that association of Rad51 with nascent DNA strands
was reduced in CPT-treated WS cells relative to WS+WRN cells
(Figure 7A), further supporting our observation on the reduced
number of Rad51 foci and chromatin binding of Rad51 in WS
cells. Evidences indicate that WRN directly interacts with
NBS1 (Cheng et al., 2004) and Rad51 (Otterlei et al., 2006),
and its interaction with MRE11 is mediated via NBS1 (Cheng
et al., 2004). Therefore, it is possible that WRN, NBS1, Rad51,
and MRE11 assemble onto nascent DNA strands not as a
complex but via pairwise interactions.
DISCUSSION
Here, we report a previously uncharacterized nonenzymatic role
for WRN in the stabilization of nascent DNA strands in response
to replication stress. We found that the nuclease activities of
WRN were not required for the maintenance of nascent DNA
strands in response to replication breaks. The N-terminal FHA
domain of NBS1 recruits WRN to the replication-associated
DSBs to limit the nuclease activity of its C-terminal binding part-
ner, MRE11, on the newly replicated genome. Notably, WRN
functions together with Rad51 to block the MRE11-mediated
degradation of nascent DNA strands. Overall, our findings reveal
that WRN, NBS1, and Rad51 cooperatively protect collapsed
replication forks to maintain genome stability (Figure 7B). See
also the Supplemental Information.
A unique finding of our study is that the physical presence of
WRN at replication-associated DSBs, rather than its enzymatic
activities, is critical for the protection of nascent DNA strands.
This is evident from our observation that the nascent DNA
Figure 7. WRN, NBS1, Rad51, and MRE11 Assemble onto Nascent
DNA Strands to Maintain Genome Stability in Response to Replica-
tion Stress
(A) WRN, NBS1, Rad51, and MRE11 associate with nascent DNA strands. WS
and WS+WRN cells were labeled with IdU for 60 min and then treated with
1 mM CPT for 5 hr. Cells were crosslinked with paraformaldehyde and the
chromatin fraction (input) was subjected to coimmunoprecipitation using
anti-BrdU (IdU) antibodies. Western blots were probed with anti-WRN, anti-
MRE11, anti-NBS1, anti-Rad51, and anti-Histone 3 (H3).
(B) A model depicting the choreography of WRN, NBS1, Rad51, and MRE11
action in the maintenance of nascent DNA strands in response to replication-
associated DSBs. See also Figure S6.
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strands are not degraded in WS cells expressing exonuclease-
or helicase-defective WRNs (Figures 3G and 3H). The nascent
DNA strands were degraded when recruitment of WRN to the
replication-associated DSBs was blocked in wild-type cells by
expression of the WRN-WRN interaction domain (Figure S4B).
In support of our findings, a previous report indicated that
WRN plays a structural role during DSB repair by protecting
DSB ends from enzymatic degradation (Chen et al., 2003), and
another study found that WRN forms complexes with a range
of DNA structures independently of its catalytic activities (Ka-
math-Loeb et al., 2012). Our identification of the nonenzymatic
contribution of WRN in the stabilization of nascent DNA tracts
clarifies why WS patients are symptomatic even though most
of the WRN mutations identified result in premature termination
of WRN protein leading to a loss of WRN nuclear localization
rather than to mutations that eliminate exonuclease or helicase
activity.
Our results revealed that nascent DNA strands are shortened
more in CPT-treated cells deficient in WRN and Rad51 than in
cells treated with CPT and either WRN or Rad51 shRNA alone
(Figures 6C and 6D), suggesting that WRN and Rad51 function
additively to maintain newly replicated DNA. This is in contrast
to replication fork protection functions of BRCA2 and FA factors.
BRCA2 and FA factors functions are epistatic with Rad51
function (Schlacher et al., 2011, 2012). There are a number of po-
tential explanations for this puzzling observation. Evidence indi-
cates that CPT can induce both replication fork stalling and
breaks. In the absence of WRN, Rad51 may collaborate with
BRCA2 and FA factors to maintain the nascent DNA strands in
response to CPT-induced stalling of replication forks. In support
of this possibility, replication fork stalling caused by low-dose
CPT or short-term HU treatments did not shorten the nascent
DNA strands in WS cells (Figures 1D and 1E). On the other
hand, in the absence of Rad51, WRN can bind to replication
breaks and may be sufficient to block the MRE11-mediated
degradation of nascent DNA strands. Alternatively, WRN may
interact with Rad52 via its C-terminal domain (Baynton et al.,
2003) to protect newly synthesized DNA from MRE11. These
possibilities can be tested by identifying and mutating the
Rad51/Rad52 interaction domain in WRN and by examining
the ability of WRN mutants to protect nascent DNA strands.
Furthermore, in the absence of both WRN and Rad51, it is prob-
able that both stalled and broken replication forks are degraded
by the MRE11 and, therefore, more shortening of nascent DNA
strands in CPT-treated WRN- and Rad51-deficient cells was
observed than in cells deficient in either Rad51 or WRN. Despite
unknowns, our study, together with other reports, clearly indi-
cates that Rad51 together with BRCA2/FA factors or with WRN
blocksMRE11-mediated degradation of both stalled and broken
replication forks, respectively.
We found that WRN is somehow involved in the stabilization of
Rad51 at replication-associated DSBs (Figures S5C–S5E). This
result was totally unexpected, because there is no evidence for
the WRN-mediated stabilization of Rad51 at replication breaks.
However, the mechanism by which WRN directly or indirectly
stabilizes Rad51 at replication breaks is unclear. WRN is shown
to directly interact with Rad51 (Otterlei et al., 2006), and this
interaction may facilitate the stability of Rad51 at replication
breaks. In the absence ofWRN, Rad51 loads onto the replication
breaks but might immediately be unloaded. This can happen
either passively due to lack of WRN at the breaks or actively dis-
lodged by other proteins. For example, Bloom syndrome protein
and/or RecQL5 might disrupt Rad51 filaments (Bugreev et al.,
2007; Hu et al., 2007) in the absence of WRN; however, further
experiments are required to support this notion. Nevertheless,
our study together with other studies (Schlacher et al., 2011,
2012) suggest that Rad51 prevents MRE11-mediated degrada-
tion of nascent DNA strands through two parallel, yet coopera-
tive, pathways: (1) Rad51 cooperates with BRCA2 and FA
factors to stabilize nascent DNA strands in response to stalled
replication forks (Schlacher et al., 2011, 2012) and (2) Rad51
collaborates with WRN to maintain nascent DNA strands in
response to replication breaks.
Mutations in WRN, NBS1, and MRE11 genes lead to WS,
Nijmegen breakage syndrome (NBS), and Ataxia telangiecta-
sia-like disorder (ATLD), respectively. Individuals with these
syndromes are all at risk for development of cancer. What is
the link between unprotected replication forks and genome
instability? The presence of a large number of chromosomal ab-
errations in CPT-treated WRN-defective cells suggests that
maintenance of nascent DNA strands is critical for the prevention
of chromosomal instability. Though exposure of WS cells to
CPT compromises cell survival (Poot et al., 1999), some cells
with chromosomal aberrations enter mitosis. Every subsequent
round of replication is expected to increase the overall mutation
level in surviving cells. Therefore, the biological significance of
unprotected replication forks is high, because replication of a
damaged genome can provide the opportunity for genomic rear-
rangements and can increase genomic instability leading to
genetic changes required for progression from an initiated cell
to a metastatic tumor cell.
Our data suggest a model for the interplay of WRN, NBS1,
MRE11, and Rad51 in preserving genome integrity during repli-
cation (Figure 7B). NBS1 recruits WRN through the N-terminal
FHA domain and MRE11 via its C-terminal domain to the repli-
cation-associated DSBs. The physical presence of WRN at
collapsed replication forks somehow stabilizes the interaction
of Rad51 with replication breaks and that limits the excessive
exonuclease activity of MRE11 on the newly replicated genome.
Thus, theWRN, NBS1, and Rad51 cooperatively protect nascent
DNA strands to maintain genome integrity during replication.
In summary, we have deciphered the molecular choreography
of WRN, NBS1, MRE11, and Rad51 that occurs at nascent DNA
strands to maintain chromosomal integrity during replication.
The coordinated action of these factors prevents the accumula-
tion of cancer-promoting mutations in humans. Our experiments
revealed a nonenzymatic role for WRN in DNA replication and




The simian virus 40 transformed control (AG07217A) and Werner syndrome
(AG11395) fibroblasts, HT1080 cells, and HeLa cells were obtained from the
ATCC. hTERT-immortalized WS and WS cells complemented with wild-type
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(WT), exonuclease defective (E84A), or helicase-defective (K577A) WRN were
described previously (Perry et al., 2006). NBS, NBS cells complemented with
full-length or FHA-deleted NBS1, and ATLD cells were described previously
(Kobayashi et al., 2010). Chinese hamster ovary cells defective in BRCA2 (V-
C8) and V-C8 cells complemented with WT BRCA2 were described previously
(Nagasawa et al., 2008).
Drugs
Aphidicolin, MRE11 inhibitor [5-(4-hydroxybenzylidene)-2-iminothiazolidin-4-
one, (mirin)], IdU (I7125), CldU (C6891), hydroxyurea, and camptothecin
were obtained from Sigma. Rad51 inhibitor [(E)-3-benzyl-2(2-(pyridine-3-yl)vi-
nyl)quinazolin-4(3H)-one, (B02)] was purchased from Calbiochem.
DNA Fiber Assay
DNA fiber technique was performed as previously described (Petermann et al.,
2010; Schlacher et al., 2011). Briefly, 2.5 3 105 cells were labeled with IdU
(150 mM) for 30 min, washed four times with warm PBS, and exposed to
1 mMCPT for 1–5 hr. After three washes with warm PBS, both labeled and un-
labeled cells were trypsinized and mixed at 1:15 ratio (labeled:unlabeled) and
lysed on a clean glass slide in 20 ml of lysis buffer (0.5%SDS, 50mMEDTA, and
200 mM Tris-HCl [pH 7.4]) for 8 min, and slides were tilted slightly (15 angle)
to help DNA spread slowly. Subsequently, slides were immunostained with
anti-BrdU antibodies, and the DNA fiber lengths were measured using Axiovi-
sion Software. See also Supplemental Information.
Statistical Analysis
The Student’s t test was performed to calculate the level of significance and a
value of p < 0.05 was considered statistically significant. GraphPad Prism
(version 6.0) was used to calculate DNA-fiber-length distribution and for mak-
ing the graphs.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.10.025.
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